December 18, 2019

TMIST Trial Enrollment Reaches 20,000 – Sites Double in 2019

The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) has now enrolled more than 20,000 patients and secured 100 of the planned 150 study sites. However, more sites and patients are needed for TMIST — the largest randomized, controlled breast cancer screening trial ever conducted.

TMIST is the first randomized, controlled trial to identify women in which digital breast tomosynthesis (DBT) may outperform two-dimensional (2D) digital mammography in reducing advanced breast cancer development.

“Interest in TMIST increases as providers learn more about this groundbreaking study. In 2019, the number of patients enrolled increased 400 percent while the number of TMIST sites doubled. I strongly urge facilities with tomosynthesis and digital mammography to visit and contact TMIST staff to take part,” said TMIST Principal Investigator Etta Pisano, MD, FACR.

TMIST will also create the world’s largest curated dataset of breast cancer screening clinical data, images and biospecimens to help researchers tailor future screening to a woman’s individual risk.

“The momentum that is reflected in community interest in TMIST is a reminder of the continuing importance of this question of defining optimal mammography,” said Peter O’Dwyer, MD, co-chair of the ECOG-ACRIN Cancer Research Group, which is leading TMIST.

“It is fantastic to see TMIST hit the milestone of 20,000 subjects enrolled! The hard work of the study team, our NCI partners and the entire breast imaging and cancer clinical trials communities is generating the momentum needed to make TMIST a truly landmark study,” said Mitchell Schnall, MD, co-chair of the ECOG-ACRIN Cancer Research Group.

Significant funding from the National Cancer Institute, part of the National Institutes of Health, supports TMIST participation. The benefits for participating sites, described in this pocket card, as well as this video, have attracted interest from a wide range of mammography clinics. Women have access to the trial through non-academic, community-based women’s health services, large health systems and freestanding radiology sites alike.

“TMIST reimbursement for each patient enrolled and each screening exam performed, payment for exams provided to women who qualify for charity care at a site, and a possible $30,000 advance to help hire a TMIST-dedicated research assistant are drawing interest,” said Pisano.

Dr. Pisano will hold an informational session April 9, 2020, at the Global Breast Cancer Conference 2020 (GBCC 2020) in Seoul, Korea.

Medical imaging providers can visit to find out how and why to take part in the world's largest randomized, controlled breast cancer screening trial.

Email with any questions regarding TMIST.